Request Demo

Last update 08 May 2025

GAST

Last update 08 May 2025

Basic Info

Synonyms

Big gastrin, G14, G17

+ [16]

Introduction

Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine.

Drugs associated with GAST

Polyclonal antibody stimulator(Aphton Corp.)

Target

GAST

Mechanism

Gastrin-17 inhibitors [+1]

Active Org.

Aphton Corp.

Originator Org.

Aphton Corp.

Active Indication

Pancreatic Cancer [+1]

Inactive Indication

Adenocarcinoma of large intestine [+6]

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

GAST targeted ASO (NCI)

Target

GAST

Mechanism

Gastrin-17 inhibitors

Active Org.

National Cancer Institute [+1]

Originator Org.

National Cancer Institute [+1]

Active Indication

Pancreatic Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

TYG-100

Target

GAST

Mechanism

Gastrin-17 inhibitors

Active Org.

OncoQR ML GmbH

Originator Org.

OncoQR ML GmbH

Active Indication

Pancreatic Cancer [+1]

Inactive Indication

Breast Cancer

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with GAST

NCT00020787

/ CompletedPhase 3IIT

An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.

Start Date01 Jul 2001

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

NCT02118077

/ CompletedPhase 3

A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

Start Date01 Apr 2001

Sponsor / Collaborator

Cancer Advances, Inc.

NCT02118064

/ CompletedPhase 2

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

Start Date01 Mar 2001

Sponsor / Collaborator

Cancer Advances, Inc.

100 Clinical Results associated with GAST

100 Translational Medicine associated with GAST

0 Patents (Medical) associated with GAST

8,986

Literatures (Medical) associated with GAST

01 Jun 2025·Journal of Translational Autoimmunity

Monitoring the follow-up of autoimmune chronic atrophic gastritis using parietal cell antibodies and markers of gastric function

Review

Author: Bizzaro, Nicola ; Antico, Antonio ; Panozzo, Maria Piera

Increased interest in the pathogenesis and the evolution of autoimmune chronic atrophic gastritis (A-CAG) has led to the search for serological markers that can be used to detect changes in the gastric mucosa at an early stage and to monitor the course of the disease. Parietal cell autoantibodies have been proposed as suitable immunological markers of atrophic damage, as they can be detected in the serum when symptoms of gastritis are not yet present. However, the utility of measuring only the level of parietal cell autoantibodies in the follow-up of A-CAG does not appear to suffice. Recent evidence has suggested that, in monitoring A-CAG, parietal cell antibodies should be associated with an evaluation of gastric function through biochemical and hormonal tests, such as pepsinogens and gastrin 17. This integrated approach will allow for the more effective real-time monitoring of the state of the gastric mucosa. As A-CAG is a progressive disorder associated with an increased risk of gastric cancer and neuroendocrine tumors, the precise follow-up of patients with gastric atrophy needs to be better defined. Further longitudinal studies in large cohorts must be performed with long-term follow-up.

01 May 2025·American Journal of Physiology-Cell Physiology

Blocking dopamine receptor 2 decreases gastrin levels in H. pylori-infected mice through increasing gastric somatostatin content

Article

Author: Zhang, Yue ; Chen, Meng-Fei ; Zhang, Xiao-Li ; Zhu, Jin-Xia ; Shen, Qian-Ying ; Song, Jin ; Zheng, Li-Fei ; Li, Zhe-Hong ; Wang, Yan-Lin ; Lian, Dong-Bo ; Qi, Yao ; Zhou, Yue-Yue

We report novel findings that blocking D2Rs, not D1Rs, decreased the number of gastric gastrin-positive cells and gastrin levels in H. pylori-infected mice. Gastric gastrin secretion induced by DA was indirectly mediated via D2Rs, which suppressed SOM release. These results provide an experimental basis for local regulation of gastric gastrin secretion by DA through D2Rs, offering a potential strategy for preventing and treating high gastrin levels in H. pylori infection.

19 Apr 2025·American Journal of Clinical Pathology

Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter-negative atrophic gastritis

Article

Author: Chen, Feidi ; Gonzalez, Raul S

AbstractObjectivesAtrophic gastritis (AG) is characterized by atrophy of gastric glands—in particular, oxyntic glands—in the setting of chronic inflammation; it is often autoimmune. The diagnosis is confirmed by immunohistochemistry (IHC) for gastrin (to confirm biopsy site), and pathologists often use IHC for neuroendocrine markers to evaluate for enterochromaffin-like cell hyperplasia (ECL-H). The utility of neuroendocrine staining is unclear, and we undertook this study to determine whether ECL pattern provided any additional information in cases of Helicobacter-negative AG.MethodsWe reviewed clinicopathologic findings in 184 cases from 184 patients with histologic AG and no evidence of Helicobacter infection. Using neuroendocrine IHC markers, cases were divided into 3 groups: Group 1 showed complete ECL-H (both qualitative and quantitative criteria met), group 2 showed focal ECL-H (qualitative but not quantitative criteria met), and group 3 showed no ECL-H (neither criteria met).ResultsGroup 1 patients were more likely to have positive autoantibody serologies (73%, P = .0007 vs group 2) and higher mean gastrin levels (700 pg/mL, P = .017 vs group 3), and only these patients developed gastric neuroendocrine tumors. Group 2 patients were more likely to take proton pump inhibitors (64%, P = .0002 vs group 1). Group 3 patients were more likely to be male (70%, P = .008 vs group 1) and to have microcytic anemia (44%, P = .022 vs group 2) and less likely to have intestinal metaplasia (50%, P = .044 vs group 1).ConclusionsStratification based on degree of ECL-H is not necessary for diagnosis of AG but does lead to statistically significant clinical and pathologic differences among groups.

News (Medical) associated with GAST

21 Nov 2022

·www.businesswire.com

What's Next for World Tumor Marker Testing Market (2022): Sector to Witness Dynamic Changes the Next Five Years - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "2022 What's Next for World Tumor Marker Testing Market - High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers" report has been added to ResearchAndMarkets.com's offering. The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Regions Asia-Pacific, Europe, Latin America, Middle East, North America Country Analyses Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam Business Opportunities and Strategic Recommendations Specific new product development opportunities with potentially significant market appeal during the next five years. Design criteria for new products. Alternative market penetration strategies. Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Tests Oncogenes Biochemical Markers Growth Factors Colony Stimulating Factors Hormones Immunohistochemical Stains Lymphokines ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Supplier Shares, Sales and Volume Forecasts Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test. Five-year test volume and sales forecasts for major cancer diagnostic assays. Instrumentation Review Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment Assessment of latest technologies and their potential applications for cancer diagnostic testing. Review of competing/complementing technologies. Companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. The companies analyzed in the report include: Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Ortho-Clinical Diagnostics, Perkin Elmer, Qiagen, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others. For more information about this report visit https://www.researchandmarkets.com/r/ffjqzd

Diagnostic ReagentsASCO

21 May 2017

·www.bioportfolio.com

US Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities [Updated: 11082016] Prices from USD $9800

Complete report $9,800.nbsp; DataPack test volumes, sales forecasts, supplier shares $6,400. VPG Market Research's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. nbsp; Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Business Opportunities and Strategic Recommendations Specific new product development opportunities with potentially significant market appeal during the next five years. Design criteria for new products. Alternative market penetration strategies. Potential market entry barriers and risks. Cancer Diagnostic Testsmdash;Over 200 current and emerging assays including: ACTH, AFP, Beta2 Microglobulin, CA 153/27.29, CA 199, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, ColonSpecific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, NeuronSpecific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Market Segmentation Analysis Sales and market shares of major suppliers, by individual cancer diagnostic test. Fiveyear test volume and sales forecasts for major cancer diagnostic tests by market segment, including: Hospitals Commercial/Private Laboratories Physician Offices/Group Practices Cancer Clinics Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. Cancer statistics, etiology and recent developments. Current and Emerging Products Review of over 200 current and emerging cancer diagnostic tests, including: Biochemical Markers Oncogenes Growth Factors Hormones Colony Stimulating Factors Lymphokines Immunohistochemical Stains, and others. Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices. Technology Review Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing. Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments Strategic assessments ofnbsp;major suppliers and startup firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in Ramp;D. Contains 620 pages and 103 tables

Antibody

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

GAST

Basic Info

Related

Analysis